Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the second quarter of its fiscal year 2009 ended December 31, 2008.

    Second Quarter of Fiscal Year 2009 Highlights

    -- Revenue was $32.9 million, up 24.1% from the corresponding quarter
       ended December 31, 2007
    -- Gross profit was $25.8 million, up 30.8% from the corresponding
       quarter ended December 31, 2007, and gross margin was 78.3%,
       compared to 74.3% in the corresponding quarter ended December 31,
       2007
    -- Operating income was $11.4 million, up 34.7% from the corresponding
       quarter ended December 31, 2007
    -- Net income was $5.4 million, or $0.11 per fully diluted share, up
       from $5.2 million, or $0.02 per fully diluted share, a year ago
    -- Non-GAAP adjusted net income was $7.0 million, or $0.71 per weighted
       average share, up 28.8% from non-GAAP adjusted net income of $5.4
       million, or $0.56 per fully diluted share, for the quarter ended
       December 31, 2007
    -- The board of directors approved a $2 million share buyback program
    -- An Assets Transfer Contract was signed in January to acquire
       Shandong Hongrui Pharmaceutical Factory ("Hongrui")
    -- A new website was launched: http://www.genesispharmaceuticals.com/

"We are pleased to report that Genesis Pharmaceuticals continued to show solid financial performance in the second quarter of our fiscal year 2009. Increased sales of Itopride Hydrochloride Granules and Baobaole Chewable Tablets led to strong revenue and operations income growth," said Mr. Wubo Cao, Chairman and CEO of Genesis. "And, sales o
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... LA (PRWEB) June 02, 2015 ... gene synthesis to improve protein expression, announced the formation ... includes six executives and entrepreneurs with a broad range ... industries. , The team includes: , Jimmy Roussel, ... , Roussel has a background in technology and marketing. ...
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... N.J. , June 1, 2015  Novartis ... clinical study of CTL019, an investigational chimeric antigen ... potential in the treatment of specific types of ... conducted by the University of Pennsylvania,s Perelman School ... refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... 8 AGA Medical today issued the,following response to ... purported victory Occlutech GmbH had achieved in the AIPPI ... a,proceeding of some sort was conducted before the AIPPI ... is false,and misleading. AGA has not been involved in ...
... Exelixis,Inc. (Nasdaq: EXEL ) will release its ... February 14, 2008 after the markets close.,The announcement will ... ET/ 2:00,p.m. PT, in which Exelixis management will discuss ... may be accessed in the Event,Calendar page under Investors ...
... today announced that its first quarter fiscal year 2008 financial,results will ... financial results, Biodel,s senior management team will,host a conference call to ... February 14, 2008 Schedule:, 8:00 a.m. ... will be distributed by PR Newswire, 8:20 a.m. ...
Cached Biology Technology:AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe 2Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008 2Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008 3
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Diego State University and the University of California have been ... on an unusual whale species and have discovered a new ... in Finite Element Modeling (FEM), Computed tomography (CT) scanning, and ... and anatomy of a Cuviers beaked whale when a sonar ...
... Your mother always told you to do your geometry ... like Parkinsons and Alzheimers, this advice turns out to ... landscape of proteins, shape determines the all-important function of ... molecule responsible for Parkinsons binds with the cell membrane, ...
... As organic farming becomes more common, methods to ... In a recent study in Journal of Environmental ... determine if non-organic, synthetic fertilizers were used on ... Murciano de Investigacin y Desarrollo Agrario y Agrario ...
Cached Biology News:How is that whale listening? 2It's all about geometry: Protein contact surfaces hold key to cures 2It's all about geometry: Protein contact surfaces hold key to cures 3Is it organic or not? 2
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
SAPK/JNK Antibody...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: